No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PCRX240719P20000
- 0.55
- +0.30+120.00%
15min DelayClose Jul 19 15:59 ET
0.55High0.30Low
0.30Open0.25Pre Close32 Volume539 Open Interest20.00Strike Price1.11KTurnover0.00%IV-0.41%PremiumJul 19, 2024Expiry Date0.63Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma35.22Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
J.P. Morgan Maintains Pacira BioSciences(PCRX.US) With Buy Rating
J.P. Morgan analyst Hardik Parikh maintains $Pacira BioSciences(PCRX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 50.0% and a total average return of -3.2%
Pacira BioSciences: Medicare and Medicaid Propose New Reimbursement for Exparel
By Stephen Nakrosis Pacira BioSciences said the U.S. Centers for Medicare and Medicaid Services have proposed new reimbursement for its Exparel non-opiod pain relief medicine in all outpatient
Express News | Pacira BioSciences Announces Centers For Medicare And Medicaid Services Issued Proposed Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Rule For 2025; Proposes New Reimbursement For EXPAREL
Express News | Centers for Medicare and Medicaid Propose New Reimbursement for Exparel in All Outpatient Surgical Environments Beginning January 1, 2025
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
PDF Version-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital
Comments
Recent insider share sale and lack of insider buying in the past year may concern investors. Despite some alignment between management and smaller shareholders, caution is advised due to recent insider selling activity.
Pacira BioSciences Independent Director Gary Pace Sells 85% Of Holding 1
Pacira BioSciences' moderate net income growth is seen as a positive despite a low ROE. The growth could be due to good management decisions or a low payout ratio, as it doesn't pay dividends. Analysts predict future earnings momentum.
1
Multiple insiders selling shares over the past year could be a red flag. However, insider ownership level shows alignment between management and smaller shareholders. Lack of insider purchases in the past year calls for caution.
The market seems to tolerate EPS decline but last year's worse-than-average performance may indicate long term investor concerns.
$Pacira BioSciences(PCRX.US$ $Flexion Therapeutics Inc(FLXN.US$ On October 12, Pacira BioSciences announced that it has entered into a definitive agreement to acquire Flexion Therapeutics For $8.50 per share, or approximately $430 million, in cash to enhance its non-opioid pain portfolio. The deal also includes contingent valuable rights worth up to $8.00 per share, which are tied to Zilretta sales targets and FDA approvals for FX201 and FX301.
3
Read more